These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 4028627)

  • 41. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteins--a placebo-controlled and double blind study.
    Richelsen B; Kristensen K; Pedersen SB
    Eur J Clin Nutr; 1996 Dec; 50(12):811-5. PubMed ID: 8968702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computational insights on molecular interactions of acifran with GPR109A and GPR109B.
    Adepu KK; Kachhap S; Bhandari D; Anishkin A; Chintapalli SV
    J Mol Model; 2022 Jul; 28(8):237. PubMed ID: 35900600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics.
    Goel H; Dunbar RL
    Curr Atheroscler Rep; 2016 Apr; 18(4):17. PubMed ID: 26932224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A.
    Li G; Deng X; Wu C; Zhou Q; Chen L; Shi Y; Huang H; Zhou N
    J Biol Chem; 2011 Sep; 286(36):31199-212. PubMed ID: 21768093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
    Vosper H
    Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.
    LaRosa JC; Miller VT; Edwards KD; DeBovis MR; Stoy DB
    Artery; 1987; 14(6):338-50. PubMed ID: 3314798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia.
    Hoeg JM; Schaefer EJ; Romano CA; Bou E; Pikus AM; Zech LA; Bailey KR; Gregg RE; Wilson PW; Sprecher DL
    Clin Pharmacol Ther; 1984 Oct; 36(4):555-65. PubMed ID: 6383687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.
    Hoeg JM; Maher MB; Bou E; Zech LA; Bailey KR; Gregg RE; Sprecher DL; Susser JK; Pikus AM; Brewer HB
    Circulation; 1984 Dec; 70(6):1004-11. PubMed ID: 6388897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlled trial of acifran in type II hyperlipoproteinemia.
    Hunninghake DB; Edwards KD; Sopko GS; Tosiello RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):313-7. PubMed ID: 4028627
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.